[{"id":"15ebc24f-836d-4955-b1c1-9b9491f8cda7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895735","created_at":"2021-05-20T11:54:07.989Z","updated_at":"2024-07-02T16:34:26.348Z","phase":"Phase 2","brief_title":"Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","source_id_and_acronym":"NCT04895735","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • MTAP • TYMS","pipe":" | ","alterations":" PD-L1 expression • TYMS expression","tags":["PD-L1 • MTAP • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 06/03/2025","primary_completion_date":" 06/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2024-06-13"},{"id":"a6714b7e-8c09-40c6-82d5-27418f5ba30c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00059930","created_at":"2021-01-18T00:07:52.504Z","updated_at":"2024-07-02T16:35:44.034Z","phase":"Phase 1","brief_title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","source_id_and_acronym":"NCT00059930","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ERCC1 • TYMS","pipe":"","alterations":" ","tags":["ERCC1 • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • dexamethasone • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/01/2003","start_date":" 01/01/2003","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-07-04"},{"id":"2899977f-33b8-402b-9cd9-34e4a5304048","acronym":"","url":"https://clinicaltrials.gov/study/NCT00935090","created_at":"2021-01-18T03:37:28.639Z","updated_at":"2024-07-02T16:35:48.859Z","phase":"","brief_title":"3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer","source_id_and_acronym":"NCT00935090","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"],"overall_status":"Suspended","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-05-05"},{"id":"ee9d2948-e174-4b7d-b507-9603eb76e47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05476432","created_at":"2022-07-27T13:54:36.196Z","updated_at":"2024-07-02T16:35:59.364Z","phase":"Phase 3","brief_title":"HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study","source_id_and_acronym":"NCT05476432","lead_sponsor":"Sun Yat-sen University","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2022-12-09"},{"id":"31a315ca-0665-4fb8-b8a9-bc26bbb5b17c","acronym":"FOLFA","url":"https://clinicaltrials.gov/study/NCT02384759","created_at":"2021-01-18T11:21:59.164Z","updated_at":"2024-07-02T16:36:14.164Z","phase":"Phase 2","brief_title":"Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers","source_id_and_acronym":"NCT02384759 - FOLFA","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-04-04"},{"id":"c3fca746-2c87-4c39-b71e-3fcf60265718","acronym":"PHOENIX","url":"https://clinicaltrials.gov/study/NCT03740893","created_at":"2021-01-18T18:19:29.637Z","updated_at":"2025-02-25T15:08:06.285Z","phase":"Phase 2","brief_title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer","source_id_and_acronym":"NCT03740893 - PHOENIX","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2020-02-21"},{"id":"d21eaf49-ee7f-4da5-977a-cfbd0e3676b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03741829","created_at":"2021-01-18T18:19:42.728Z","updated_at":"2024-07-02T16:36:50.428Z","phase":"","brief_title":"TS Overexpression in SCLC: Mechanism and Therapeutic Targeting","source_id_and_acronym":"NCT03741829","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" TYMS","pipe":" | ","alterations":" TYMS expression","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/14/2017","start_date":" 06/14/2017","primary_txt":" Primary completion: 01/03/2020","primary_completion_date":" 01/03/2020","study_txt":" Completion: 01/03/2020","study_completion_date":" 01/03/2020","last_update_posted":"2020-02-05"},{"id":"ae9c765d-a27e-451d-9978-da5127fe63a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00449137","created_at":"2021-01-18T01:35:21.197Z","updated_at":"2024-07-02T16:37:27.058Z","phase":"Phase 1","brief_title":"Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment","source_id_and_acronym":"NCT00449137","lead_sponsor":"University of Miami","biomarkers":" TYMS","pipe":" | ","alterations":" TYMS expression","tags":["TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2005","start_date":" 06/01/2005","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2016-12-15"},{"id":"8e1bb0a8-fb40-48f3-8d78-11c776c28c97","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898846","created_at":"2021-01-18T03:27:14.501Z","updated_at":"2024-07-02T16:37:28.825Z","phase":"","brief_title":"Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery","source_id_and_acronym":"NCT00898846","lead_sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","biomarkers":" MSI • TYMS","pipe":"","alterations":" ","tags":["MSI • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegafur/uracil"],"overall_status":"Completed","enrollment":" Enrollment 1111","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2016-09-28"},{"id":"fc18a3b4-d245-4d27-ba5a-baa9f7f17ef0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01194453","created_at":"2021-01-18T04:46:49.793Z","updated_at":"2024-07-02T16:37:31.280Z","phase":"Phase 2","brief_title":"Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01194453","lead_sponsor":"Sun Yat-sen University","biomarkers":" TYMS • RRM1","pipe":" | ","alterations":" TYMS expression","tags":["TYMS • RRM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • pemetrexed • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 288","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":" Completion: 08/01/2012","study_completion_date":" 08/01/2012","last_update_posted":"2016-06-16"},{"id":"c1ec60c4-9f82-4094-9abd-1661946e576d","acronym":"AALL03B2","url":"https://clinicaltrials.gov/study/NCT00898469","created_at":"2021-01-18T03:27:05.433Z","updated_at":"2024-07-02T16:37:32.292Z","phase":"","brief_title":"Identifying Risk Factors for Bone Tissue Death in Young Patients With Acute Lymphoblastic Leukemia Treated on Clinical Trial CCG-1882","source_id_and_acronym":"NCT00898469 - AALL03B2","lead_sponsor":"Children's Oncology Group","biomarkers":" TYMS","pipe":"","alterations":" ","tags":["TYMS"],"overall_status":"Completed","enrollment":" Enrollment 671","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2016-05-11"}]